Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers: The Market's Panic Is Irrational
04:39am, Sunday, 07'th Dec 2025
Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
02:56pm, Thursday, 04'th Dec 2025
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglut
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
10:15pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
08:06pm, Wednesday, 03'rd Dec 2025
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
03:42pm, Tuesday, 02'nd Dec 2025
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday,
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
05:15am, Sunday, 30'th Nov 2025
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9 - , 30 - , and 60-fold higher
BEIJING , Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
01:49pm, Tuesday, 25'th Nov 2025
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
12:39pm, Tuesday, 25'th Nov 2025
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs
There's still hope GLP-1 drugs could slow the second-biggest type of dementia
04:57pm, Monday, 24'th Nov 2025
Can GLP-1s treat vascular dementia? One study failed, but some researchers are holding out hope.
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
12:35pm, Monday, 24'th Nov 2025
Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare.
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in the health, safety and rapid
Hims & Hers: The Growth Story Is Outside GLP-1s
08:23am, Monday, 24'th Nov 2025
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, and the stock tumbles
07:30am, Monday, 24'th Nov 2025
Novo Nordisk's stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer's.
